Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chicken Pox Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

NCT00197015
View directory record Official record
Conditions
Hepatitis A
Interventions
Havrix®, M-M-R®II, VARIVAX®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 13 Months
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
42
States / cities
Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

NCT00871117
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
11
States / cities
Antioch, California • Daly City, California • Hayward, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Zoster Eye Disease Study

NCT03134196
View directory record Official record
Conditions
Herpes Zoster Ophthalmicus
Interventions
Masked Placebo, Masked Oral Valacyclovir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
71
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 22, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to Varicella-Zoster Vaccination and Infection

NCT00921999
View directory record Official record
Conditions
Chickenpox, Herpes Zoster
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

NCT03604406
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

NCT01132716
View directory record Official record
Conditions
Herpes Zoster, Shingles, Genital Herpes
Interventions
Valacyclovir Hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 3 Interventional

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352
View directory record Official record
Conditions
VZV Infection After Bone Marrow Transplantation
Interventions
Acyclovir
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1985 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

NCT01228838
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
NGX-1998, Placebo Liquid
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Huntsville, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting

NCT00689013
View directory record Official record
Conditions
Herpes Zoster
Interventions
Personalized letter, Flyer advertisement, Newspaper press release
Other
Lead sponsor
University of Tennessee
Other
Eligibility
60 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Johnson City, Tennessee • Manchester, Tennessee • Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2009 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

NCT00851786
View directory record Official record
Conditions
Herpes Zoster, HIV Infections
Interventions
ZOSTAVAX, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 22, 2026, 8:59 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

NCT07406360
View directory record Official record
Conditions
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions
MMRVNS, MMRV
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Months to 6 Years
Enrollment
1,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Walnut Creek, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

NCT05084508
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
41
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 22, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional

Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

NCT00005009
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Varivax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
4
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Not applicable Interventional

Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer

NCT04540081
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Tobacco Use Cessation, Obesity, Pneumonia, Bacterial, Shingles, Hepatitis C
Interventions
Epic Healthy Planet Population Health Module
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 80 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia

NCT00478179
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
Transdermal/Patch (Bupivacaine TTS [Eladur™])
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
La Jolla, California • Loma Linda, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2009 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

NCT00034710
View directory record Official record
Conditions
Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions
Capsaicin Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744
View directory record Official record
Conditions
Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
Interventions
GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Tai Chi Chih and Varicella Zoster Immunity

NCT00029484
View directory record Official record
Conditions
Varicella
Interventions
Tai chi chih
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
60 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

NCT03798691
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 22, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

NCT05554068
View directory record Official record
Conditions
Shingles
Interventions
Shingrix
Drug
Lead sponsor
Loyola University
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

NCT00831103
View directory record Official record
Conditions
Herpes Zoster
Interventions
EPB-348, Valacyclovir
Drug
Lead sponsor
Epiphany Biosciences
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 22, 2026, 8:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 22, 2026, 8:59 PM EDT